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Introduction
Bleeding is a major complication of oral anticoagulants that leads to serious morbidity and substantial burden on healthcare resources. In the USA, the annual cost of hospitalization associated with warfarin-related bleeding was estimated at US$24 347-41 903 per patient [1] . With the rapid development of non-vitamin-K antagonist oral anticoagulants (NOACs), the burden of bleeding related to these agents is expected to rise. Dabigatran is the first NOAC approved as an alternative treatment to warfarin in patients with non-valvular atrial fibrillation (NVAF) [2] . At present, dabigatran remains the most frequently used NOAC and there is an increasing trend for its use [3] . However, several cases of serious hospitalized bleeds associated with dabigatran have been reported [4] [5] [6] [7] . When comparing dabigatran with warfarin, the literature provides inconsistent results, as some studies found a higher risk of hospitalized bleeding with dabigatran over warfarin [8] [9] [10] , whereas some studies reported no increased risk [11] [12] [13] . Indeed, dabigatran works rapidly following its initiation [14] ; hence it may lead to more early-onset bleeds. In contrast, warfarin may take weeks to achieve anticoagulation stability following its initiation [14] , resulting in less bleeding. Further investigation of bleeding risk with dabigatran over warfarin is therefore needed.
Because oral anticoagulants might precipitate bleeding from pre-existing lesions [15] , early recurrence is plausible after resuming treatment. Early readmission is costly and particularly common among high-risk and older patients [16] , who are the typical users of oral anticoagulants. In the USA, reducing early hospital readmissions (i.e. 30 days) is a policy priority aimed at improving healthcare quality and is considered a pay-for-performance indicator of inpatient services by policymakers [16, 17] . Approximately two-thirds of hospitals in the USA received penalties because of excessive 30-day readmission rates in 2013 [18] . Of note, antithrombotic drugs are one of the most common medications implicated in hospital admissions, with bleeding as the major cause of admission [19, 20] . However, there is limited information about the rate of 30-day readmission with bleeding related to dabigatran and warfarin use.
With a view to addressing these knowledge gaps, this study was conducted to compare the incidence of bleeding-related hospital admission and 30-day readmission in patients with NVAF treated with dabigatran vs. warfarin.
Materials and methods

Data source
This study used the population-wide electronic medical records of the Clinical Data Analysis and Reporting System (CDARS) of the Hong Kong Hospital Authority (HA), which is the sole public-funded healthcare provider in Hong Kong. HA is serving a population of over seven million through healthcare facilities including hospitals, specialist clinics and general outpatient clinics [21] . Electronic patient records, such as demographics, date of registered death, date of consultation, drug dispensing records, date of hospital admission and discharge, diagnoses, procedures and laboratory tests, of the HA are centralized in the CDARS for research and audit purposes. Data in the CDARS have been extensively used for various epidemiological studies [22] [23] [24] [25] [26] [27] [28] [29] [30] . Previous studies have demonstrated the high coding accuracy in the CDARS, including the diagnosis records for AF, gastrointestinal bleeding, intracranial hemorrhage and ischemic stroke, with positive predictive values of 90-100% [23, 24, 26] . Detailed descriptions of the CDARS were previously published [24, 28, 31] .
Patient records in the CDARS are anonymized to protect patient identity. The study protocol was approved by the Institutional Review Board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster (reference number: UW13-468). Informed patient consent was not required as the data used in this study were anonymized.
Study design and study population
This was a population-based retrospective cohort study. Patients who had their first recorded AF (i.e. newly diagnosed with AF) between 1 January 2010 and 31 December 2014 were selected from the CDARS based on International Classification of Disease, Ninth Revision, Clinical Modification (ICD-9-CM) codes (Table S1 ). In order to identify patients with NVAF, patients diagnosed with valvular heart disease or hyperthyroidism, or who underwent valve replacement (ICD-9-CM; Table S1 ) at or prior to their first AF occurrence, were excluded. Patients with transient AF (ICD-9-CM; Table S1), missing date of birth or sex information, aged<18 years or who died at first AF occurrence were also excluded. The index date was defined as the date of the first recorded prescription of dabigatran or warfarin following AF diagnosis. To select new users of dabigatran and warfarin, patients who were exposed to either drug within 180 days prior to the index date were excluded. Patients with a history of bleeding were also excluded to eliminate any residual effect of previous bleeding on subsequent bleeding risk after commencement of dabigatran or warfarin (Fig. 1) .
The follow-up for each patient commenced from the index date until the end of the study period (30 September 2015), death, switching to other oral anticoagulants (e.g. apixaban, dabigatran, rivaroxaban and warfarin) or discontinuation of treatment (defined as >5 days gap between consecutive prescription refills), whichever came first. We used a 5-day permissible medication gap to determine discontinuation of treatment because this was the mean time interval between prescription refills of dabigatran and warfarin in our cohort. Sensitivity analyses were conducted to examine the robustness of the study results using different permissible medication gaps.
Outcome definitions
The outcomes of interest were the first and 30-day recurrent bleeding that required inpatient admission since commencement of dabigatran and warfarin. Bleeding was defined as a composite endpoint of gastrointestinal bleeding (GIB), intracranial hemorrhage (ICH) and other bleeding, which included epistaxis, hematuria, hemarthrosis, hemopericardium, hemoptysis and hemorrhage from the kidney, throat and vagina [26, 32] . Information on hospitalization for bleeding was identified from discharge diagnosis records in the CDARS using ICD-9-CM codes (Table S1 ). Hospitalizations nested within 24 h were regarded as the same episode. The total length of stay was calculated as the time interval between the admission date and discharge date. For patients who survived the first hospitalized bleeding and were continuously prescribed with their initial anticoagulants upon discharge (i.e. no medication gap of > 5 days between consecutive prescription refills), we examined the risk of 30-day readmission with bleeding in respective treatment groups. Readmission with bleeding was defined as subsequent inpatient admission with a discharge diagnosis of bleeding within 30 days of discharge from the first bleeding episode [33] .
Propensity score matching
Propensity score (PS) matching was used to account for the potential selection bias in treatment allocation [34] . The PS was estimated by logistic regression based on age, sex, index year, number of hospitalization(s) within 1 year prior to index date, and medical history (yes/no) of congestive heart failure, hypertension, diabetes mellitus, ischemic stroke/transient ischemic attack/systemic embolism, vascular disease, myocardial infarction, renal disease, pneumonia or fall; the Charlson comorbidities index; and recent use (≤ 90 days prior to index date) of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, beta-blocker, amiodarone, dronedarone, aspirin, clopidogrel, non-steroidal anti-inflammatory drugs (NSAIDs), histamine type-2-receptor antagonists (H2RAs), proton pump inhibitors (PPIs), statins and selective serotonin reuptake inhibitors. The baseline medical history of each patient was identified from all diagnosis records in the CDARS dated before his or her individual index date (ICD-9-CM; Table S1 ). Dabigatran and warfarin cohorts were 1:1 matched by the greedy matching algorithm, which has been demonstrated to perform well in both actual and simulation studies [35] . Standardized differences were calculated to assess the balance of baseline characteristics between treatment groups. A standardized difference of < 0.1 was considered negligible [36] .
Statistical analysis
Baseline characteristics were expressed as mean AE standard deviation and frequencies (percentages) for continuous and categorical variables, respectively. To account for the excess zero counts in hospital admissions, the zeroinflated negative binomial regression model was used to compare the incidence rate of first hospitalized bleeding between dabigatran and warfarin users [37] . The risks of readmission with bleeding in respective treatment groups were illustrated by Kaplan-Meier (KM) curves and compared using Cox proportional hazards regression model with adjustment for the length of stay and type of bleeding (GIB, ICH or other bleeding) in the initial bleeding episode (Fig. 2) . The Cox proportional hazards regression model would have been used for all statistical analyses if the model assumptions were satisfied. As the hazard rates of the first hospitalized bleeding with dabigatran and warfarin were not proportional and thus did not satisfy the proportional-hazard assumption in the Cox model, a negative binomial regression model was used as an alternative. A two-sided P-value < 0.05 was considered as statistically significant. Statistical analyses were independently conducted by WCYL and KKCM as quality assurance. SAS (version 9.3; SAS Institute, Inc, Cary, NC, USA) was used for statistical analyses.
Additional analyses
Subgroup analyses were conducted by stratifying bleeding into three subtypes: GIB, ICH and other bleeding. Further analysis was conducted for dabigatran 110 mg b.i.d. only, which is the most common dosage of dabigatran prescribed in Asian countries [24, 38] . In our main analysis, discontinuation of treatment was defined as > 5 days of gap between consecutive prescription refills. Sensitivity analyses were conducted using varying 10-day and 20-day permissible medication gaps to define discontinuation of treatment. Finally, because warfarin can take up to 6 weeks to achieve full anticoagulation effect [14] , we studied the risk of readmission within 60 days of discharge to capture any later bleeding in additional analyses.
In post hoc analysis, we stratified patients into aged < 75 years and aged ≥ 75 years, and patients on warfarin into having good and poor international normalized ratio (INR) control using the Rosendaal method [39] , where the INR was aimed to be 2.0-3.0. Intervals between INR records that were ≥ 8 weeks were not interpolated [40] . INR records measured in the first 28 days of warfarin or during hospitalization were excluded as they were unlikely to reflect the actual quality of anticoagulation control [26] . Good INR control was defined as time in therapeutic range (TTR) ≥ 65% [41] .
Results
Baseline characteristics
There were 51 946 patients newly diagnosed with AF identified in the CDARS from 1 January 2010 through to 31 December 2014. Following patient exclusion, 8309 new dabigatran and warfarin users were eligible for PS matching (Fig. 1) between two INR tests was 46 days (standard deviation = 35 days). There were 3559 warfarin users with valid INR test interval(s) for calculation of TTR and of these, 26% had TTR ≥ 65%. Among patients who had TTR < 65%, 85% of their out-of-range INR records were below 2.0. After PS matching, 5160 patients were included in the analysis. All baseline characteristics were balanced between treatment groups ( Table 1 ). The mean follow-up of the PS-matched cohort was 425 AE 434 days.
First hospital admission with bleeding
After PS matching, there were 151 (5.9%) and 172 (6.7%) patients hospitalized with bleeding in the dabigatran and warfarin groups, respectively. The mean INR of warfarin users at discharge was 1.8 (standard deviation = 0.6).
The incidence rates of hospital admission were comparable between dabigatran and warfarin users (5.0 vs. 5.8
per 100 patient-years; incidence rate ratio [IRR], 0.92; 95% CI, 0.66-1.28) ( (Table S3) . Sensitivity analyses using different medication gaps also yielded similar results (Table S4) . Post hoc analysis showed that dabigatran was associated with (Table S5) .
Thirty-day readmission with bleeding
There were 13.5% of dabigatran patients and 5.1% of warfarin patients readmitted to hospital with bleeding within 30 days of discharge (Table 3 ). The KM curve of readmission is illustrated in Fig. 2 . Over the 30 days of discharge from the first episode, a total of 28 patients on dabigatran and 21 patients on warfarin were censored because of death (n = 2 vs. n = 0), discontinuation of treatment (n = 23 vs. n = 21) or reaching the end of the study period (n = 3 vs. n = 0), respectively. Cox regression analysis showed that dabigatran use was significantly associated with a higher risk of 30-day readmission (HR, 2.87; 95% CI, 1.10-7.43) compared with warfarin. The hazard ratio for dabigatran 110 mg b.i.d. was similar but did not reach statistical significance (HR, 2.15; 95% CI, 0.74-6.26) (Table S6 ). Subgroup analysis for bleeding subtypes indicated that dabigatran tended to have a higher risk of readmission compared with warfarin for GIB (HR, 1.89; 95% CI, 0.39-9.20) and other bleeding (HR, 2.67; 95% CI, 0.78-9.11), yet the differences did not reach statistical significance (Table 3) . The results were robust to all sensitivity analyses (Table S7) . No significant differences in readmission were observed between patients aged < 75 years and ≥ 75 years (P-value for interaction = 0.77) (Table S5 ). Further analysis revealed that the risk of readmission between dabigatran and warfarin became statistically non-significant within 60 days of discharge (HR, 1.89; 95% CI, 0.89-4.04) ( Table 3) .
Discussion
Bleeding is a primary complication of oral anticoagulation that is also associated with the risk of recurrence [42] . In this population-based cohort study, we found that PS, propensity score; py, patient-years; IRR, incidence rate ratio; CI, confidence interval. †Other bleeding includes epistaxis, hematuria, hemarthrosis, hemopericardium, hemoptysis, and hemorrhage from the kidney, throat and vagina. ‡Adjusted IRRs were obtained using zeroinflated negative binomial regression to account for excess zero counts in hospital admissions. *P < 0.05. PS, propensity score; HR, hazard ratio; CI, confidence interval. Values are expressed as: number of patients re-hospitalized within 30 days of discharge/total number of hospitalized patients. †Other bleeding includes epistaxis, hematuria, hemarthrosis, hemopericardium, hemoptysis, and hemorrhage from the kidney, throat and vagina. ‡Unable to estimate hazard ratio as there were no warfarin patients re-hospitalized with intracranial hemorrhage. *P < 0.05.
dabigatran use was associated with a comparable rate of first hospital admission but a higher risk of 30-day readmission with respect to bleeding when compared with warfarin. Stratified analyses of bleeding subtypes revealed that dabigatran use was associated with a higher incidence of GIB yet a lower incidence of ICH over warfarin. The results are consistent for low-dose dabigatran at 110 mg b.i.d. and robust to all sensitivity analyses. Oral anticoagulants are among the most common class of medications implicated in hospital admissions as a result of adverse drug events [43, 44] . Patients who experienced complications of anticoagulants are at high risk of hospital readmissions [44] , which have been reported to occur most commonly within the first 30 days of discharge and involve longer stays and higher management costs than the initial episode in patients with AF [45] . Therefore, there is a pressing need for reducing early readmission rates in AF patients. In the USA, the Centers for Medicare and Medicaid Services began penalizing hospitals for excessive rates of 30-day readmission in October 2012 [17] . To date, over 2000 hospitals have been penalized, resulting in an estimated USD 280 million penalties in the fiscal year 2013 [46] . Similarly, a non-payment policy for 30-day readmissions was introduced in the UK in April 2011, where commissioners will not pay for a proportion of 30-day acute readmissions that are judged to have been avoidable [47] . These policies highlight the value of data regarding readmission, both from the perspective of the patient and the healthcare system as a whole. A higher risk of 30-day readmission for bleeding was observed for dabigatran compared with warfarin in patients with NVAF and this finding has important implications for clinical practice and healthcare policies.
Our findings that dabigatran was associated with a higher risk of 30-day readmission with bleeding may be explained by several factors. Firstly, dabigatran achieves full anticoagulation effect more quickly than warfarin. Although it takes approximately 2-3 days for dabigatran to reach steady-state levels, it could take up to 6 weeks for warfarin to achieve full anticoagulation effect [14] . Therefore, dabigatran might lead to more early-onset bleeds compared with warfarin. Consistent with this hypothesis, we noted that the difference in the risk of readmission between dabigatran and warfarin became statistically non-significant within 60 days of discharge. Secondly, there is limited guidance on prevention of recurrent bleeding with dabigatran. Dosing adjustment based on INR has been the traditional strategy to prevent warfarin-related bleeding [48] ; however, routine monitoring of dabigatran is not yet recommended and there are no approved means of monitoring anticoagulation levels of dabigatran [49] . Existing coagulation tests for dabigatran, including calibrated dilute thrombin time (dTT) and ecarin clotting time (ECT), are not approved by the US Food and Drug Administration as a reliable measure of dabigatran concentrations [49, 50] . There is also no consensus on the optimal therapeutic range of dabigatran plasma levels [51, 52] . As a result, effective dose adjustment of dabigatran to prevent re-bleeding is challenging.
In contrast, warfarin has well-established means of monitoring. The correlation between INR outside therapeutic range (typically 2.0-3.0 in patients with NVAF) [53] and clinical outcomes with warfarin has been demonstrated in meta-analyses and population-based studies [26, 54, 55] . The ability to monitor anticoagulation in warfarin might facilitate the assessment of the readiness for discharge from hospital, as well as dosing management to minimize bleeding risk after discharge when required. Our study found that the mean INR of warfarin users at discharge was close to 2.0, which might reflect a conservative strategy to reduce bleeding risk in this cohort of Chinese patients, who are perceived to have a high risk of bleeding [56] . However, the necessity of drug monitoring in dabigatran remains under strong debate [50, 52] . Another potential factor to consider is the substantial variability of dabigatran concentrations across individuals [52] . In the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial, patients on a fixed dose of dabigatran 150 mg b.i.d. had a wide range of plasma concentrations from 2.3 to 1000 ng mL À1 [52] . The risk of major bleeding was reported to increase rapidly with dabigatran plasma concentration, from 2-3% at 50 ng mL À1 to over 9% at 300 ng mL À1 [52] . Because oral anticoagulants may exacerbate bleeding from preexisting lesions, this variability of plasma concentration could affect the likelihood of early re-bleeding with dabigatran [57] .
In this study, we noted a higher incidence of hospitalization for GIB with dabigatran vs. warfarin, which is consistent with previous meta-analyses of randomized controlled trials [15] and observational studies [58] . Importantly, we observed an increased risk of GIB with dabigatran 110 mg b.i.d. compared with warfarin, in contrast to the RE-LY trial, which reported a comparable risk [2] . However, in the subgroup analysis of patients aged ≥ 75 years in the RE-LY trial, dabigatran 110 mg b.i.d. was associated with a 40% higher risk of GIB compared with warfarin [59] . Given that the mean age of this cohort was 74 years (standard deviation = 10 years), our results consistently reflect a higher risk of GIB with dabigatran compared with warfarin in an older population, who are the common users of oral anticoagulants. Post hoc, we also found an effect of interaction between treatment and age on bleeding risk, where dabigatran compared with warfarin was associated with a lower risk of overall bleeding in patients aged < 75 years, but with a trend towards a higher risk in those aged ≥ 75 years, consistent with the RE-LY trial [59] . The lower incidence of ICH with dabigatran irrespective of age has been consistently reported in the literature, with a risk ratio of approximately 0.2 to 0.4 [2, 13, 60, 61] , in line with our study findings. In addition, our findings suggest that GIB remains the most common type of bleeding associated with dabigatran use. GIB has been the key complication in the use of dabigatran since the premarketing stage [2] . Concerns over GIB heightened following the release of a safety announcement from the US Food and Drug Administration in 2014, which suggested that dabigatran is associated with a higher risk of GIB compared with warfarin [62] . Although the reversal agent of dabigatran was approved in October 2015 [63] , there is lack of highlevel evidence of its effectiveness and safety in real-life settings. Therefore, continual post-marketing surveillance on the risk of bleeding is warranted in dabigatran users [5, 62] .
To our knowledge, no population-based studies have yet been conducted to compare the readmission rate for bleeding with dabigatran and warfarin in real-life practice. We utilized the large electronic patient record database of the HA in Hong Kong, which has recognized strengths in providing high-quality data for largescale post-marketing surveillance studies [22] [23] [24] [25] [26] [27] [28] [29] . We applied a new user design to eliminate the residual effect of previous exposure on the study outcomes. Patients with a history of outcome were also excluded to minimize residual confounding. To further account for the potential confounding factors, our study cohort was matched by PS with respect to patient characteristics, comorbidities and concurrent medications, where all the characteristics were balanced between groups after PS matching.
Several limitations are worthy of mention. Similar to other healthcare databases, the CDARS does not capture over-the-counter medications such as aspirin; hence we cannot control for the effect of such medications in our analyses. However, HA is the only source of public healthcare services in Hong Kong, and the service is highly subsidized (85-98%) by the government [64] . As a result, patients with chronic illness requiring long-term treatment, such as AF, commonly opt for the services of HA instead of purchasing full-cost medications from elsewhere [64] . Therefore, the impact of uncaptured medications on our results is anticipated to be minimal. We accounted for important confounding factors and conducted sensitivity analyses to test for the robustness of the results, and the results were found to be consistent in all analyses. However, by the nature of pharmacoepidemiological studies, we cannot exclude the possibility of an unmeasured residual confounding effect. Similar to the case of other epidemiological healthcare databases, we used ICD codes to identify bleeding events, of which the coding accuracy has been shown to be high in the CDARS (PPV = 95-100%) [24, 26] . However, we are unable to classify bleeding by severity using the International Society on Thrombosis and Haemostasis (ISTH) bleeding definition, because information such as the extent of hemoglobin level drop and the number of units of blood used in transfusion are not available in the CDARS. Finally, as the sample size was reduced in the stratification analyses for bleeding subtypes and the power is therefore reduced, the stratified analyses might not be statistically powerful enough to detect a significant difference. Further study is needed to confirm these results. Areas for future research may include development of predictive tools for readmission among NVAF patients prescribed different types of oral anticoagulants [65, 66] , and effective measures for prevention of 30-day readmission among oral anticoagulant users.
Conclusion
When compared with warfarin, dabigatran was associated with a comparable incidence of hospital admissions but a higher risk of 30-day readmission with respect to bleeding. Considering that dabigatran achieves full anticoagulation more rapidly compared with warfarin, close early monitoring of patients initiated on anticoagulation following hospital discharge and strategies to reduce recurrence of bleeding with dabigatran are warranted. fees from Eisai, Ferring, Menarini and Takeda, and also serves on the advisory board of AbbVie, BoehringerIngelheim and Janssen. The other authors state that they have no conflict of interests.
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